Alnylam Pharmaceuticals this week announced that it would offer for sale 8.625 million of its shares at $10.75 per share.
The company's shares have been trading around $12.50 this week.
Alnylam is offering 7.5 million shares to the public, and the underwriters of the offering have exercised an option to purchase 1.125 million additional shares.
The transaction, which would pull in $86.9 million for the company, is expected to close on Feb. 21.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
